Risperidone in the early treatment of first-episode psychosis: A two-year follow-up study;Tratamiento precoz con risperidona de primeros episodios psicóticos: Dos años de seguimiento

Actas Espanolas de Psiquiatria

Volumn 30, Issue 3, 2002, Pages 142-152

  Gutierrez Fraile M ^a   Segarra Echevarria R ^a   Gonzalez Pinto Arrillaga A ^a   Martinez Junquera G ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

Effectiveness; First episode; Long term follow up; Risperidone; Tolerance

Indexed keywords

RISPERIDONE;

ADULT; AGED; AMENORRHEA; ARTICLE; BEHAVIOR; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; PARKINSON DISEASE; PSYCHOSIS; QUALITY OF LIFE; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RISPERIDONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036061528     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. The diagnosis of schizophrenia: A review of onset and duration issues
2. Schizophrenia: The epidemiological horizon
3. Schizophrenics kills themselves too. A review of risk factors for suicide
4. The psychobiology of the acute schizophrenic episode
5. Risperidone: New horizons for the schizophrenic patients
6. Adverse effects of antipsychotic agents. Do newer agents offer advantages?
7. The negative symptoms of schizophrenia
8. Neurocognitive impairment in schizophrenia and how it affects treatment options
9. Efectos secundarios extrapiramidales de los fármacos antipsicóticos
10. An overview of side effects caused by typical antipsychotics
11. Uso de fármacos antipsicóticos en otras enfermedades psiquiátricas
12. The role of serotonin in the pathophysiology and treatment of schizophrenia
13. Serotonin-dopamine interaction and its relevance to schizophrenia
14. Acción farmacológica de los antipsicóticos y su relación con los mecanismos neurobiológicos de la esquizofrenia
15. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin S2 and dopamine D2 antagonistic properties
16. The biochemical profile of risperidone a new antipsichotic
17. Risperidone versus haloperidol in the treatment of chronic schizophrenic subjects: A multicentre double-blind comparative trial
18. Risperidone in the treatment of schizophrenia
19. Risperidone: Clinical satety and efficacy in schizophrenia
20. A canadian multicenter placebo-controlled study of fixed doses of riperidone and haloperidol in the treatment of chronic schizophrenic patients
21. Risperidone in the treatment of chronic schizophrenic patients: A multinational, multicentre double-blind, parallel-group study versus haloperidol
22. Risperidone side effects
23. Risperidona en la prevención de recaídas a largo plazo en 215 pacientes con esquizofrenia
24. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder
25. Risperidone, negative symptoms and cognitive deficit in schizophrenia: An open study
26. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
27. Risperidone versus haloperidol on secondary memory: Can newer medications aid learning?
28. Symptoms in neuroleptic-naive, first-episode schizophrenia: Response to risperidone
29. Extrapiramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone
30. Risperidone in first-episode schizophrenia: Improvement in symptoms and pre-existing extrapiramidal signs
31. Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study
32. A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic
33. Risperidone in the treatment of first episode psychosis
34. Course of treatment response in first-episode and chronic schizophrenia
35. The natural course of schizophrenia: A review of first-admission studies
36. Neuroleptics and the natural course of schizophrenia
37. Research and treatment strategies in first-episode psychoses
38. A comparison of observatial studies and randomized, controled trials
39. Long term morbidity associated with delayed treatment of first admission schizophrenic patients: A re-analysis of the Camarillo State Hospital day
40. First-episode schizophrenia early intervention and medication discontinuation in the context of course and treatment
41. Duration of psychosis and outcome in first-episode schizophrenia
42. Sequential cross-sectional and 10 year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia
43. Psychopathology executive and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia
44. Duration of initially untreated psychosis: Cognition and domains of psychopathology in the long-term
45. Duration of initially untreated psychosis: Impact on quality of life at first presentation with schizophrenia
46. EPPIC: An evolving system of early detection and optimal management
47. Pharmacologic treatment of first-episode schizophrenia: Early intervention is key to outcome
48. Pharmacotherapy of first-episode schizophrenia
49. The development of treatment resistance in patients with schizophrenia: A clinical and pathophysiologic perspective
50. Prolonged recovery in first-episode psychosis
51. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis
52. Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol dose
53. Prediction of outcome following a first episode of schizophrenia a follow-up study of Northwick Park first episode study subjects
54. Cantabria first episode schizophrenia study: Three-year follow-up
55. Three-year outcome of first-episode psychoses in an established community psychiatric service
56. Reduction of hospital days in chronic schizophrenic patient treated with risperidone: A retrospective study
57. Risperidona en el tratamiento de la reagudización de los síntomas de la esquizofrenia
58. Risperidone and Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): Efficacy and tolerability results of an international naturalistic study
59. Minimizing the non-extrapiramidal side-effects of antipsychotics